DISH.L

BigDish Plc
Amala Foods PLC - Further re Temporary Suspension
1st December 2023, 15:01
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4486V
Amala Foods PLC
01 December 2023
 

 

Amala Foods Plc

("Amala" or the "Company")

 

Further re: Temporary Suspension

 

Amala Foods Plc (LON: DISH) is pleased to announce a further update following the Temporary Suspension of its listing on the Standard Segment of the Official List of the Main Market that was announced on 9 November 2023. 

The Company is pleased to update the market that the transaction that was announced on 9 November 2023 regarding the group of Dialysis Care Plus Inc (Proposed Reverse Takeover) is progressing.  Notwithstanding the combined market capitalisations of the target and the Company being anticipated to be less than £30 million, as the Company was deemed to be a cash shell immediately before 3 December 2021, it falls within the scope of the transitional provisions in respects of Listing Rule 2.2.7R.

Whilst the Directors are confident that the Proposed Reverse Takeover will be concluded prior to the end of the first quarter of 2024, there remain a number of regulatory consents unrelated to the post transaction market capitalisation that are normal for a transaction of this type that need to be obtained prior to the Proposed Reverse Takeover being concluded.  Therefore, there can be no guarantee that the Proposed Reverse Takeover will be concluded, but the Company's shares will remain suspended while the transaction is ongoing.  The Company will update the market in due course, including further details regarding the business of the Dialysis Care Plus Inc group.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION EU 596/2014 ("MAR").

 

Enquiries:

 

Jonathan Morley-Kirk, Non-Executive Chairman

jmk@bluebirdmv.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURBSBDDLUGDGXB]]>
TwitterFacebookLinkedIn